Skip to main content

Excellence at the point of care

We are committed to helping pioneer a new era in diagnostic technology, where the results from DNA and RNA-based tests can be obtained in the moment of need, at the point of care.

Founded in 2010 with a vision to bring centralized lab quality results to the point of care, we are prioritizing the development of infectious disease test panels for women’s and sexual health providers.

Our History


The COVID-19 pandemic accelerated the development of molecular point-of-care platforms to bring rapid respiratory testing closer to patients.

Learn More


At Talis Biomedical, we are pioneering science and technology to diagnose infectious disease rapidly, accurately, and directly at the point of care. Fueled by excellence and clinical rigor, we’re developing a robust menu of tests for women’s and sexual health.

Contact Us

One system, multiple applications

Access to molecular diagnostics at the point of care, enbales timely results for actionable decision making. In the future,
our Talis One portfolio of diagonositc tests will include solutions for multiple infectious disease states in a variety of settings.

Learn More


The need for molecular testing at the point of care continues.


Point-of-care testing could help ensure more infected patients receive treatment, potentially stopping the transmission cycle.


Working to reduce the spread of gonorrhoea by developing a rapid and accurate point-of-care test


1375 West Fulton Market
Suite 700
Chicago, Illinois 60607


+1 855 956-3594

© Talis Biomedical Corporation. All Rights Reserved.

Talis One is a registered trademark of Talis Biomedical Corporation.

* Testing solutions are currently in development and not available for sale.

* †The Talis Biomedical One Test System is not authorized, cleared, or approved by the FDA and is not available for sale.